Tag: OncBioMune

August 31, 2017

OncBioMune Sends Study Protocol for Review

OncBioMune Pharmaceuticals announced the protocol for their planned Phase II study of ProscaVax treating prostate cancer is being reviewed by...
August 24, 2017

Final Patient Completes Treatment in First Leg of OncBioMune's Clinical Trial

OncBioMune Pharmaceuticals announced the final patient for the first stage of their phase 1 trial of ProscaVax for prostate cancer...
August 22, 2017

OncBioMune Submits Documents to Commercialize Norepinefrine in Mexico

OncBioMune Pharmaceuticals announced it has submitted documents for the official transfer of the Mexican rights to market Norepinefrine in the...
August 10, 2017

OncBioMune To Exclusively Distribute Lipomed Drugs in Mexico

OncBioMune Pharmaceuticals announced it was designated as the exclusive distributor for the product portfolio of Lipomed AG.
August 3, 2017

OncBioMune Applies to Commercialize Anti-Rabies Drug in Mexico

OncBioMune Pharmaceuticals submitted an application with the Mexican equivalent of the US Food and Drug Administration to commercialize a licensed...
June 21, 2017

OncBioMune Gets Patent for Cancer Vaccine in Mexico

OncBioMune Pharmaceuticals obtained a patent from the Mexican Institute of Industrial Property protecting the intellectual rights of the company's ProscaVax...
June 7, 2017

OncBioMune Receives Patent for ProscaVax in Hong Kong

OncBioMune Pharmaceuticals obtained a patent in Hong Kong for ProscaVax, the company's immunotherapeutic cancer vaccine.